Bionano Genomics Inc (BNGO) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.46 is considered Undervalued compared with the five-year average of -5.97. The fair price of Bionano Genomics Inc (BNGO) is between 4.39 to 4.76 according to relative valuation method. Compared to the current price of 1.12 USD , Bionano Genomics Inc By Undervalued By 74.55%.

Relative Value

Fair Zone

4.39-4.76

Current Price：1.12

74.55%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Bionano Genomics Inc (BNGO) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Bionano Genomics Inc (BNGO) has a current Price-to-Book (P/B) ratio of 0.31. Compared to its 3-year average P/B ratio of 0.54, the current P/B ratio is approximately -42.18% higher. Relative to its 5-year average P/B ratio of 2.22, the current P/B ratio is about -86.02% higher. Bionano Genomics Inc (BNGO) has a Forward Free Cash Flow (FCF) yield of approximately -115.42%. Compared to its 3-year average FCF yield of -279.78%, the current FCF yield is approximately -58.75% lower. Relative to its 5-year average FCF yield of -168.23%, the current FCF yield is about -31.39% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BNGO competitors is 6.76, providing a benchmark for relative valuation. Bionano Genomics Inc Corp (BNGO.O) exhibits a P/S ratio of 0.46, which is -93.19% above the industry average. Given its robust revenue growth of 21.31%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BNGO increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BNGO in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BNGO currently overvalued or undervalued?

What is Bionano Genomics Inc (BNGO) fair value?

BNGO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Bionano Genomics Inc (BNGO) is between 4.39 to 4.76 according to relative valuation method.

How does BNGO's valuation metrics compare to the industry average?

The average P/S ratio for BNGO's competitors is 6.76, providing a benchmark for relative valuation. Bionano Genomics Inc Corp (BNGO) exhibits a P/S ratio of 0.46, which is -93.19% above the industry average. Given its robust revenue growth of 21.31%, this premium appears sustainable.

What is the current P/B ratio for Bionano Genomics Inc (BNGO) as of Mar 04 2026?

As of Mar 04 2026, Bionano Genomics Inc (BNGO) has a P/B ratio of 0.31. This indicates that the market values BNGO at 0.31 times its book value.

What is the current FCF Yield for Bionano Genomics Inc (BNGO) as of Mar 04 2026?

As of Mar 04 2026, Bionano Genomics Inc (BNGO) has a FCF Yield of -115.42%. This means that for every dollar of Bionano Genomics Inc's market capitalization, the company generates -115.42 cents in free cash flow.

What is the current Forward P/E ratio for Bionano Genomics Inc (BNGO) as of Mar 04 2026?

As of Mar 04 2026, Bionano Genomics Inc (BNGO) has a Forward P/E ratio of -0.46. This means the market is willing to pay $-0.46 for every dollar of Bionano Genomics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Bionano Genomics Inc (BNGO) as of Mar 04 2026?

As of Mar 04 2026, Bionano Genomics Inc (BNGO) has a Forward P/S ratio of 0.46. This means the market is valuing BNGO at $0.46 for every dollar of expected revenue over the next 12 months.

BNGO Valuation